OncologyKnife fightData as of 2026-09-04
Pancreatic Cancer is one of the more crowded fields on the map: 9 companies in the clinic, ranking it 12th of 299 indications by competitor count. The median competitor is worth $371M, below the $1.20B median of the universe.
That gap is the crowding discount. When a field is deep the market pays less per company, because the same eventual revenue has to be split across more shots on goal.
IBRX carries 57% of the $15.3B competing here, more than the other 8 companies combined.
$2.4B of allocated capital sits in Pancreatic Cancer, 83rd of 299 indications, and 1 of the 9 companies are pure plays that trade on this indication alone.
| Ticker | Company | Lead asset | Phase | Trials | Market cap | Pure play | Indications | Next catalyst |
|---|---|---|---|---|---|---|---|---|
| RCUS | Arcus Biosciences | Quemliclustat | Phase 3 | 3 | $3.8B | No | 5 | 14 Nov 2026 |
| ARTV | Artiva Biotherapeutics | Immuncell-LC | Phase 3 | 1 | $544M | No | 4 | 31 Dec 2028 |
| IMRX | Immuneering | Atebimetinib | Phase 3 | 3 | $326M | Yes | 1 | 31 Dec 2026 |
| IBRX | ImmunityBio | N-803 | Phase 2 | 4 | $8.7B | No | 12 | 31 Dec 2026 |
| VSTM | Verastem | Avutometinib | Phase 2 | 5 | $723M | No | 8 | 31 Dec 2026 |
| AGEN | Agenus | Botensilimab | Phase 2 | 5 | $371M | No | 7 | 31 Dec 2026 |
| MGNX | MacroGenics | Lorigerlimab | Phase 2 | 1 | $270M | No | 3 | 30 Sep 2026 |
| BCYC | Bicycle Therapeutics | Nuzefatide pevedotin | Phase 2 | 1 | $214M | No | 4 | 31 Dec 2026 |
| CATX | Perspective Therapeutics | Pb-PSV359 | Phase 1 | 1 | $356M | No | 3 | 23 Oct 2026 |
Sorted by phase, then by market capitalisation. Ticker links open the company profile. IBRX holds 57% of the $15.3B competing in this indication.
Crowded and cheaply priced. Six or more competitors and a median company below the universe median.
Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.
See every Oncology indication on the map9 US-listed companies in the $100M to $20B market cap band run clinical programmes in Pancreatic Cancer. The largest and most advanced are Arcus Biosciences (RCUS, Quemliclustat, Phase 3); Artiva Biotherapeutics (ARTV, Immuncell-LC, Phase 3); Immuneering (IMRX, Atebimetinib, Phase 3); ImmunityBio (IBRX, N-803, Phase 2); Verastem (VSTM, Avutometinib, Phase 2). The full list of 9 is in the table on this page.
Of the 9 clinical-stage programmes in Pancreatic Cancer, 3 are in Phase 3 or filed, 5 are in mid-stage development and 1 is in early-stage development.
IBRX is the largest developer in Pancreatic Cancer, holding 57% of the $15.3B of market capitalisation competing in the indication. The median competitor is worth $371M.
The next dated catalyst in Pancreatic Cancer is MGNX on 30 Sep 2026. 8 dated events across the field fall in the next 12 months.
Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.
Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.
Back to the disease map